查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916714

癌症免疫療法市場預測至2032年：按類型、治療環境、技術、應用、最終用戶和地區分類的全球分析

Cancer Immunotherapy Market Forecasts to 2032 - Global Analysis By Type, Treatment Setting, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 預測，全球癌症免疫療法市場預計到 2025 年將達到 1,406.3 億美元，到 2032 年將達到 2,505.5 億美元，預測期內複合年成長率為 8.6%。

癌症免疫療法是一種利用人體自體免疫系統對抗癌症的治療策略。它並非直接攻擊腫瘤，而是增強免疫細胞辨識和摧毀癌細胞的能力。治療方法包括免疫查核點抑制劑、癌症疫苗、單株抗體和過繼性細胞療法。透過針對腫瘤特異性抗原並恢復免疫功能，免疫療法可以產生持久的療效，降低復發率，並提高存活率。這種個人化、標靶治療代表了腫瘤學領域的變革性轉折點，為難治性癌症患者帶來了新的希望。

全球癌症負擔日益加重

全球癌症發生率的不斷攀升是癌症免疫療法市場的主要驅動力。各種惡性腫瘤的日益流行，加上人口老化和生活方式相關的風險因素，使得人們對先進治療方法的需求顯著增加。由於傳統治療方法往往效果不佳，患者和醫療機構開始轉向具有標靶性和持久療效的免疫療法。日益沉重的癌症負擔促使製藥公司加強研發投入，加速了全球市場的擴張。

醫療成本不斷上漲

高昂的治療費用是癌症免疫療法普及的一大障礙。包括免疫查核點抑制劑和個人化細胞療法在內的先進治療方法，需要複雜的生產過程、專門的給藥方法和持續的監測。許多患者，尤其是在中低收入地區，面臨經濟負擔，這限制了他們獲得和接受治療的機會。此外，保險覆蓋範圍和報銷方面的挑戰進一步加重了治療的經濟負擔。這些經濟障礙減緩了市場滲透速度，並對全球腫瘤領域的永續發展構成了重大挑戰。

免疫腫瘤學的進展

免疫腫瘤學的持續進步為市場帶來了巨大的機會。新一代免疫查核點抑制劑、基因改造T細胞和聯合治療等新型療法正在提高療效並拓展治療適應症。腫瘤特異性抗原和個人化治療策略的研究進展正在改善患者的預後。此外，生技公司與大型製藥公司之間日益密切的合作正在加速藥物研發。這些創新有望創造新的收入來源並擴大市場規模。

監理和核准問題

監管和核准的挑戰對市場構成重大威脅。複雜的臨床試驗要求、嚴格的安全性和有效性標準，以及不同地區法規結構，都可能延緩產品核可。這些障礙會增加研發成本和週期，進而影響整體盈利和市場准入。核准後的監測和合規義務進一步加劇了商業化進程的複雜性。監管的不確定性，加上不斷變化的安全指南，可能會抑制創新，延緩產品應用，並為全球投資新型免疫療法的公司帶來風險。

新冠疫情的影響：

新冠疫情導致臨床試驗延長、醫院就診量減少、擇期治療受限，嚴重擾亂了市場。供應鏈中斷影響了關鍵生物製藥的生產和分銷。然而，疫情也加速了遠端醫療的普及，並凸顯了免疫治療方法的必要性。製藥公司透過實施遠端監測和安全通訊協定來應對疫情，從而減輕了長期影響。總體而言，儘管疫情初期的衝擊減緩了市場成長，但疫情後的復甦以及對免疫療法的重新關注預計將在未來幾年推動市場強勁擴張。

預計在預測期內，細胞激素細分市場將佔據最大的市場佔有率。

由於細胞激素在刺激抗腫瘤免疫反應中發揮至關重要的作用，預計在預測期內，細胞激素領域將佔據最大的市場佔有率。細胞激素能夠活化T細胞和自然殺手細胞，因此在標靶癌症治療中不可或缺。不斷增加的研究、良好的臨床結果以及基於細胞激素治療方法的核准，都在推動市場成長。此外，與其他免疫療法藥物聯合治療時療效的提升，也使細胞激素成為全球創新癌症治療策略的基石。

預計在預測期內，乳癌細分市場將呈現最高的複合年成長率。

由於公眾意識的提高和早期診斷的普及，以及對先進治療方法需求的不斷成長，預計乳癌領域在預測期內將呈現最高的成長率。包括查核點抑制劑和個人化疫苗在內的免疫療法已在乳癌患者中展現出令人鼓舞的臨床效果。生物標記識別和聯合治療策略的進步進一步提高了治療效果。因此，該領域的醫藥投資和研發活動正在增加，推動市場快速成長，並為全球患者帶來新的希望。

佔比最大的地區：

預計亞太地區將在整個預測期內保持最大的市場佔有率，這主要得益於癌症發病率的上升以及政府為改善先進療法的可及性而採取的主導。人們對創新治療方法的認知度和接受度不斷提高，加上龐大的患者群體，共同創造了巨大的市場潛力。跨國製藥公司與當地企業之間的策略合作進一步鞏固了其市場地位，使亞太地區成為癌症免疫療法持續成長的關鍵區域。

年複合成長率最高的地區：

在預測期內，北美預計將實現最高的複合年成長率，這主要得益於高額的研發投入和對創新治療方法的強力的監管支持。公眾意識的廣泛提高、早期診斷的普及以及有利的報銷政策正在加速療法的推廣應用。大型製藥公司的存在和廣泛的臨床試驗活動也推動了快速成長。包括個人化和聯合免疫療法在內的前沿研究正在推動新型治療方法的開發，使北美成為癌症免疫療法領域高成長、創新主導的中心。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，提供主要國家的市場估算和預測以及複合年成長率（註：可行性需確認）。
  • 競爭標竿分析
    • 根據主要企業的產品系列、地理覆蓋範圍和策略聯盟進行基準分析

目錄

第1章執行摘要

第2章 前言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 技術分析
  • 應用分析
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第5章 全球癌症免疫療法市場（按類型分類）

  • 免疫查核點抑制劑
    • PD-1抑制劑
    • PD-L1抑制劑
    • CTLA-4抑制劑
  • 單株抗體
  • 癌症疫苗
  • 過繼性細胞轉移療法
    • CAR-T細胞療法
    • TCR療法
    • 腫瘤浸潤淋巴細胞（TILs）
  • 細胞激素
  • 溶瘤病毒療法

6. 全球癌症免疫療法市場（依治療場所分類）

  • 醫院
  • 專科診所
  • 門診手術中心
  • 家庭醫療保健

7. 全球癌症免疫療法市場（依技術分類）

  • 基因編輯與基因工程
  • 奈米技術在免疫療法的應用
  • 生物標記伴隨診斷
  • 其他技術

第8章 全球癌症免疫療法市場（按應用分類）

  • 乳癌
  • 肺癌
  • 黑色素瘤
  • 大腸直腸癌
  • 攝護腺癌
  • 骨髓惡性腫瘤
  • 其他用途

第9章 全球癌症免疫療法市場（按最終用戶分類）

  • 研究和學術機構
  • 診斷檢查室
  • 其他最終用戶

第10章 全球癌症免疫療法市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章 企業概況

  • Amgen Inc.
  • AbbVie Inc.
  • AstraZeneca Plc
  • Johnson &Johnson
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • Merck &Co., Inc.
  • Seagen Inc.
  • F. Hoffmann-La Roche Ltd
  • BeiGene Ltd.
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Novartis AG
  • Eli Lilly and Company
  • GlaxoSmithKline Plc（GSK）
Product Code: SMRC33287

According to Stratistics MRC, the Global Cancer Immunotherapy Market is accounted for $140.63 billion in 2025 and is expected to reach $250.55 billion by 2032 growing at a CAGR of 8.6% during the forecast period. Cancer immunotherapy is a treatment strategy that leverages the body's immune system to fight cancer. Instead of directly attacking tumors, it enhances immune cells' ability to recognize and destroy cancer cells. Approaches include immune checkpoint inhibitors, cancer vaccines, monoclonal antibodies, and adoptive cell therapies. By targeting tumor-specific antigens and restoring immune function, immunotherapy can provide durable responses, reduce relapse, and improve survival. This personalized, targeted approach represents a transformative shift in oncology, offering new hope for patients with difficult to treat cancers.

Market Dynamics:

Driver:

Rising Global Cancer Burden

The increasing incidence of cancer worldwide is a key driver for the cancer immunotherapy market. Rising prevalence of various malignancies, coupled with aging populations and lifestyle-related risk factors, is creating significant demand for advanced treatments. As conventional therapies often fall short in efficacy, patients and healthcare providers are turning to immunotherapy solutions that offer targeted, durable responses. This growing cancer burden is prompting pharmaceutical companies to invest heavily in research and development, accelerating market expansion globally.

Restraint:

High Treatment Costs

High treatment costs pose a significant restraint to the adoption of cancer immunotherapy. Advanced therapies, including immune checkpoint inhibitors and personalized cell-based treatments, require complex manufacturing, specialized administration, and ongoing monitoring. Many patients, especially in low- and middle-income regions, face financial barriers, limiting access and adoption. Additionally, insurance coverage and reimbursement challenges further restrict affordability. These economic hurdles slow market penetration, posing a critical challenge to sustainable growth in the global oncology landscape.

Opportunity:

Advancements in Immuno-Oncology

Ongoing advancements in immuno-oncology present significant opportunities for the market. Novel approaches, including next-generation immune checkpoint inhibitors, engineered T-cells, and combination therapies, are enhancing efficacy and expanding treatment indications. Research breakthroughs in tumor-specific antigens and personalized therapy strategies are improving patient outcomes. Additionally, increasing collaboration between biotech companies and pharmaceutical giants is accelerating drug discovery. These innovations are expected to create new revenue streams and expand the market.

Threat:

Regulatory & Approval Challenges

Regulatory and approval challenges are a major threat to the market. Complex clinical trial requirements, stringent safety and efficacy standards, and varying regulatory frameworks across regions can delay product approvals. These hurdles increase development costs and timelines, affecting overall profitability and market entry. Post-approval monitoring and compliance obligations further complicate commercialization. Regulatory uncertainty, combined with evolving safety guidelines can hinder innovation, slow adoption, and pose risks to companies investing in novel immunotherapy therapies worldwide.

Covid-19 Impact:

The COVID-19 pandemic disrupted the market by delaying clinical trials, reducing hospital visits, and limiting elective treatments. Supply chain interruptions affected the production and distribution of critical biologics. However, the pandemic also accelerated telemedicine adoption and highlighted the need for immune-based therapies. Pharmaceutical companies adapted by implementing remote monitoring and safety protocols, mitigating long-term impact. Overall, while initial disruptions slowed growth, post-pandemic recovery and renewed focus on immunotherapies have positioned the market for strong expansion in the coming years.

The cytokines segment is expected to be the largest during the forecast period

The cytokines segment is expected to account for the largest market share during the forecast period as they crucial role in stimulating immune responses against tumors. Their ability to activate T-cells and natural killer cells makes them vital in targeted cancer therapy. Increasing research, favorable clinical outcomes, and approvals for cytokine-based therapies are driving market growth. Furthermore, combination therapies with other immunotherapeutics enhance efficacy, positioning cytokines as a cornerstone of innovative oncology treatment strategies globally.

The breast cancer segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the breast cancer segment is predicted to witness the highest growth rate, due to growing awareness, and early diagnosis are increasing demand for advanced therapies. Immunotherapy approaches, including checkpoint inhibitors and personalized vaccines, are showing promising clinical outcomes in breast cancer patients. Advances in biomarker identification and combination therapy strategies are further enhancing treatment efficacy. As a result, pharmaceutical investment and research activity are intensifying in this segment, driving rapid market growth and offering new hope to patients globally.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to growing cancer prevalence, and increasing government initiatives to improve access to advanced therapies are key contributors. Rising awareness and adoption of innovative treatments, coupled with a large patient population, create significant market potential. Strategic partnerships between multinational pharmaceutical companies and local firms further strengthen market presence, making Asia Pacific a critical region for sustained growth in cancer immunotherapy.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to high R&D investment, and strong regulatory support for innovative therapies. Widespread awareness, early diagnosis, and favorable reimbursement policies accelerate adoption. The presence of leading pharmaceutical companies and extensive clinical trial activity also fuels rapid growth. Cutting-edge research, including personalized and combination immunotherapies, is driving the development of novel treatments, positioning North America as a high-growth, innovation-driven hub for cancer immunotherapy.

Key players in the market

Some of the key players in Cancer Immunotherapy Market include Amgen Inc., AbbVie Inc., AstraZeneca Plc, Johnson & Johnson, Bristol-Myers Squibb Company, Sanofi S.A., Merck & Co., Inc., Seagen Inc., F. Hoffmann-La Roche Ltd, BeiGene Ltd., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Novartis AG, Eli Lilly and Company and GlaxoSmithKline Plc (GSK).

Key Developments:

In January 2026, Cartography Biosciences and Pfizer forged a multi year pact to unearth tumor selective antigens using Cartography's pioneering ATLAS and SUMMIT platforms, aiming to fuel next generation precision oncology with shared discovery and development efforts.

In December 2025, Pfizer has struck an exclusive global collaboration and license deal with YaoPharma, a Shanghai Fosun subsidiary, to develop, manufacture, and commercialize YP05002, an oral small molecule GLP 1 receptor agonist now in Phase I for chronic weight management.

Types Covered:

  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies
  • Cancer Vaccines
  • Adoptive Cell Transfer Therapy
  • Cytokines
  • Oncolytic Virus Therapy

Treatment Settings Covered:

  • Hospital
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Home Healthcare

Technologies Covered:

  • Gene Editing & Engineering
  • Nanotechnology in Immunotherapy
  • Biomarker & Companion Diagnostics
  • Other Technologies

Applications Covered:

  • Breast Cancer
  • Lung Cancer
  • Melanoma
  • Colorectal Cancer
  • Prostate Cancer
  • Hematologic Malignancies
  • Other Applications

End Users Covered:

  • Research & Academic Institutes
  • Diagnostic Laboratories
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Cancer Immunotherapy Market, By Type

  • 5.1 Introduction
  • 5.2 Immune Checkpoint Inhibitors
    • 5.2.1 PD-1 Inhibitors
    • 5.2.2 PD-L1 Inhibitors
    • 5.2.3 CTLA-4 Inhibitors
  • 5.3 Monoclonal Antibodies
  • 5.4 Cancer Vaccines
  • 5.5 Adoptive Cell Transfer Therapy
    • 5.5.1 CAR-T Cell Therapy
    • 5.5.2 TCR Therapy
    • 5.5.3 Tumor-Infiltrating Lymphocytes (TILs)
  • 5.6 Cytokines
  • 5.7 Oncolytic Virus Therapy

6 Global Cancer Immunotherapy Market, By Treatment Setting

  • 6.1 Introduction
  • 6.2 Hospital
  • 6.3 Specialty Clinics
  • 6.4 Ambulatory Surgical Centers
  • 6.5 Home Healthcare

7 Global Cancer Immunotherapy Market, By Technology

  • 7.1 Introduction
  • 7.2 Gene Editing & Engineering
  • 7.3 Nanotechnology in Immunotherapy
  • 7.4 Biomarker & Companion Diagnostics
  • 7.5 Other Technologies

8 Global Cancer Immunotherapy Market, By Application

  • 8.1 Introduction
  • 8.2 Breast Cancer
  • 8.3 Lung Cancer
  • 8.4 Melanoma
  • 8.5 Colorectal Cancer
  • 8.6 Prostate Cancer
  • 8.7 Hematologic Malignancies
  • 8.8 Other Applications

9 Global Cancer Immunotherapy Market, By End User

  • 9.1 Introduction
  • 9.2 Research & Academic Institutes
  • 9.3 Diagnostic Laboratories
  • 9.4 Other End Users

10 Global Cancer Immunotherapy Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Amgen Inc.
  • 12.2 AbbVie Inc.
  • 12.3 AstraZeneca Plc
  • 12.4 Johnson & Johnson
  • 12.5 Bristol-Myers Squibb Company
  • 12.6 Sanofi S.A.
  • 12.7 Merck & Co., Inc.
  • 12.8 Seagen Inc.
  • 12.9 F. Hoffmann-La Roche Ltd
  • 12.10 BeiGene Ltd.
  • 12.11 Pfizer Inc.
  • 12.12 Regeneron Pharmaceuticals, Inc.
  • 12.13 Novartis AG
  • 12.14 Eli Lilly and Company
  • 12.15 GlaxoSmithKline Plc (GSK)

List of Tables

  • Table 1 Global Cancer Immunotherapy Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Cancer Immunotherapy Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Cancer Immunotherapy Market Outlook, By Immune Checkpoint Inhibitors (2024-2032) ($MN)
  • Table 4 Global Cancer Immunotherapy Market Outlook, By PD-1 Inhibitors (2024-2032) ($MN)
  • Table 5 Global Cancer Immunotherapy Market Outlook, By PD-L1 Inhibitors (2024-2032) ($MN)
  • Table 6 Global Cancer Immunotherapy Market Outlook, By CTLA-4 Inhibitors (2024-2032) ($MN)
  • Table 7 Global Cancer Immunotherapy Market Outlook, By Monoclonal Antibodies (2024-2032) ($MN)
  • Table 8 Global Cancer Immunotherapy Market Outlook, By Cancer Vaccines (2024-2032) ($MN)
  • Table 9 Global Cancer Immunotherapy Market Outlook, By Adoptive Cell Transfer Therapy (2024-2032) ($MN)
  • Table 10 Global Cancer Immunotherapy Market Outlook, By CAR-T Cell Therapy (2024-2032) ($MN)
  • Table 11 Global Cancer Immunotherapy Market Outlook, By TCR Therapy (2024-2032) ($MN)
  • Table 12 Global Cancer Immunotherapy Market Outlook, By Tumor-Infiltrating Lymphocytes (TILs) (2024-2032) ($MN)
  • Table 13 Global Cancer Immunotherapy Market Outlook, By Cytokines (2024-2032) ($MN)
  • Table 14 Global Cancer Immunotherapy Market Outlook, By Oncolytic Virus Therapy (2024-2032) ($MN)
  • Table 15 Global Cancer Immunotherapy Market Outlook, By Treatment Setting (2024-2032) ($MN)
  • Table 16 Global Cancer Immunotherapy Market Outlook, By Hospital (2024-2032) ($MN)
  • Table 17 Global Cancer Immunotherapy Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 18 Global Cancer Immunotherapy Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
  • Table 19 Global Cancer Immunotherapy Market Outlook, By Home Healthcare (2024-2032) ($MN)
  • Table 20 Global Cancer Immunotherapy Market Outlook, By Technology (2024-2032) ($MN)
  • Table 21 Global Cancer Immunotherapy Market Outlook, By Gene Editing & Engineering (2024-2032) ($MN)
  • Table 22 Global Cancer Immunotherapy Market Outlook, By Nanotechnology in Immunotherapy (2024-2032) ($MN)
  • Table 23 Global Cancer Immunotherapy Market Outlook, By Biomarker & Companion Diagnostics (2024-2032) ($MN)
  • Table 24 Global Cancer Immunotherapy Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 25 Global Cancer Immunotherapy Market Outlook, By Application (2024-2032) ($MN)
  • Table 26 Global Cancer Immunotherapy Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 27 Global Cancer Immunotherapy Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 28 Global Cancer Immunotherapy Market Outlook, By Melanoma (2024-2032) ($MN)
  • Table 29 Global Cancer Immunotherapy Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 30 Global Cancer Immunotherapy Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 31 Global Cancer Immunotherapy Market Outlook, By Hematologic Malignancies (2024-2032) ($MN)
  • Table 32 Global Cancer Immunotherapy Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 33 Global Cancer Immunotherapy Market Outlook, By End User (2024-2032) ($MN)
  • Table 34 Global Cancer Immunotherapy Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 35 Global Cancer Immunotherapy Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 36 Global Cancer Immunotherapy Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.